Brain metastasis in human epidermal growth factor receptor 2-positive breast cancer: from biology to treatment
Radiation Oncology Journal. 2016;34(1):1-9 
Treatment challenges for community oncologists treating postmenopausal women with endocrine-resistant, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
Cancer Management and Research. 2016;Volume 8:85-94
Treatment challenges for community oncologists treating postmenopausal women with endocrine-resistant, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
Cancer Management and Research. 2016;Volume 8:127-128
Evolving landscape of human epidermal growth factor receptor 2-positive breast cancer treatment and the future of biosimilars
The Breast. 2017;32:199-216
Delaying Chemotherapy in the Treatment of Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
Clinical Medicine Insights: Oncology. 2015;9:CMO.S31586
PO74 WHICH IS MORE BENEFICIAL AS AN INITIAL THERAPY FOR THE FIRST DISTANT METASTASIS OF BREAST CANCER: CHEMOTHERAPY OR ENDOCRINE THERAPY FOR HORMONE RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE BREAST CANCER PATIENTS? A SINGLE-CENTER STUDY
The Breast. 2015;24:S47
Human Epidermal Growth Factor Receptor (HER) Family Molecular Structure
Personalized Treatment of Breast Cancer. 2016;311-322
Effect and safety of dual anti-human epidermal growth factor receptor 2 therapy compared to monotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer: a systematic review
BMC Cancer. 2014;14(1):
Impact of palbociclib combinations on treatment of advanced estrogen receptor-positive/human epidermal growth factor 2-negative breast cancer
OncoTargets and Therapy. 2016;Volume 9:6119-6125
Involvement of epidermal growth factor receptor overexpression in the promotion of breast cancer brain metastasis
Cancer. 2012;118(21):5198-5209